Outdoor light at night could be a significant risk factor in Alzheimer’s disease, according to new research from Rush.
Lead drug from J&J and Addex’s 20-year collaboration flunks Phase 2 in epilepsy
The top experimental drug stemming from Johnson & Johnson’s long-running alliance with Addex Therapeutics has failed a Phase 2 epilepsy study, casting a shadow over